Impact of antibiotic resistance on the treatment of gram-negative sepsis

Current Infectious Disease Reports

Volumn 2, Issue 5, 2000, Pages 409-416

  Baden, Lindsey R ^a   Eisenstein, Barry I ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diagn Microbiol Infect; Lactam; National Nosocomial Infection Surveillance; National Nosocomial Infection Surveillance System; Resistant Organism

Indexed keywords

EID: 0001501093     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-000-0067-z     Document Type: Article

References (41)

1. Bone RC, Grodzin CJ, Balk RA: Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997, 112:235–243.
2. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al.: Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991, 324:429–436.
3. Eisenstein BI, Zaleznik DF: Enterobacteriaceae. In Principles and Practice of Infectious Diseases. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill Livingstone; 1999:2294–2310. This chapter comprehensively reviews the Enterobacteriacae.
4. Gold HS, Moellering RC Jr: Antimicrobial-drug resistance. N Engl J Med 1996, 335:1445–1453. This article reviews the emergence of several important mechanisms of resistance in the 1990s.
5. Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System Report, Data, Summary from October 1986–April 1998, Issued June 1998. Atlanta: Public Health Service, US Department of Health and Human Services; 1998:1–25. This report analyzes data collected by the NNIS System, an ongoing national surveillance system monitoring nosocomial infection rates, organisms and resistance patterns at more than 250 hospitals. The report can be downloaded from the CDC website at.
6. Miller YW, Eady EA, Lacey RW, et al.: Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother 1996, 38:829–837.
7. Levy SB: Multidrug resistance--a sign of the times [editorial; comment]. N Engl J Med 1998, 338:1376–1378.
8. Endtz HP, Ruijs GJ, van Klingeren B, et al.: Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991, 27:199–208.
9. Glynn MK, Bopp C, Dewitt W, et al.: Emergence of multidrugresistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N Engl J Med 1998, 338:1333–1338.
10. Fridkin SK, Steward CD, Edwards JR, et al.: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999, 29:245–252. This report analyzes antibiotic resistance patterns and concomitant antimicrobial use at 41 US hospitals.
11. Yinnon AM, Butnaru A, Raveh D, et al.: Klebsiella bacteraemia: community versus nosocomial infection. QJM 1996, 89:933–941.
12. Emori TG, Culver DH, Horan TC, et al.: National nosocomial infections surveillance system (NNIS): description of surveillance methods. Am J Infect Control 1991, 19:19–35.
13. Vincent JL, Bihari DJ, Suter PM, et al.: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee JAMA 1995, 274:639–644.
14. Richards MJ, Edwards JR, Culver DH, Gaynes RP: Nosocomial infections in coronary care units in the United States. National Nosocomial Infections Surveillance System. Am J Cardiol 1998, 82:789–793. This is a careful analysis of the pathogens causing infections in US CCUs, from the NNIS database.
15. Richards MJ, Edwards JR, Culver DH, Gaynes RP: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999. 27:887–892. This is a careful analysis of the pathogens causing infections in US MICUs, from the NNIS database.
16. Fridkin SK, Welbel SF, Weinstein RA: Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am 1997, 11:479–496.
17. Miller GH, Sabatelli FJ, Hare RS, et al.: The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 1997, 24(Suppl 1):S46–62.
18. Dornbusch K, King A, Legakis N: Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients. Report from a European collaborative study. European Study Group on Antibiotic Resistance (ESGAR). Scand J Infect Dis 1998, 30:281–288.
19. Barsic B, Beus I, Marton E, et al.: Antibiotic resistance among gram-negative nosocomial pathogens in the intensive care unit: results of 6-year body-site monitoring. Clin Ther 1997, 19:691–700.
20. Pfaller MA, Jones RN, Doern GV, Kugler K: Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998, 42:1762–1770. These authors investigate antimicrobial resistance patterns for blood stream pathogens from 38 sites in the US and Canada.
21. Jones RN, Pfaller MA, Marshall SA, et al.: Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diagn Microbiol Infect Dis 1997, 29:187–192.
22. Virk A, Steckelberg JM: Clinical aspects of antimicrobial resistance [review]. Mayo Clin Proc 2000, 75:200–214.
23. Medeiros AA: Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997, 24(Suppl 1):S19-S45.
24. Pfaller MA, Jones RN, Marshall SA, et al.: Inducible amp C β-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997, 28:211–219.
25. Pitout JD, Sanders CC, Sanders WE Jr: Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. Am J Med 1997, 103:51–59.
26. Chow JW, Fine MJ, Shlaes DM, et al.: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991. 115:585–590.
27. Karas JA, Pillay DG, Muckart D, Sturm AW: Treatment failure due to extended spectrum β-lactamase [letter]. J Antimicrob Chemother 1996, 37:203–204.
28. Jacoby GA: Genetics of extended-spectrum β -lactamases. Eur J Clin Microbiol Infect Dis 1994. 13(Suppl 1):S2-S11.
29. Rice LB, Carias LL, Bonomo RA, Shlaes DM: Molecular genetics of resistance to both ceftazidime and β -lactam-β -lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to β-lactam therapy. J Infect Dis 1996, 173:151–158.
30. Romaschin AD, Harris DM, Ribeiro MB, et al.: A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods 1998, 212:169–185.
31. Carlet J: Rapid diagnostic methods in the detection of sepsis [review]. Infect Dis Clin North Am 1999, 13:483–494, xi. This is a useful review of emerging diagnostic considerations in sepsis.
32. Dutka-Malen S, Evers S, Courvalin P: Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995, 33:1434.
33. Einsele H, Hebart H, Roller G, et al.: Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997. 35:1353–1360.
34. Flahaut M, Sanglard D, Monod M, et al.: Rapid detection of Candida albicans in clinical samples by DNA amplification of common regions from C. albicans-secreted aspartic proteinase genes. J Clin Microbiol 1998, 36:395–401.
35. Kane TD, Alexander JW, Johannigman JA: The detection of microbial DNA in the blood: a sensitive method for diagnosing bacteremia and/or bacterial translocation in surgical patients. Ann Surg 1998, 227:1–9.
36. Wallet F, Roussel-Delvallez M, Courcol RJ: Choice of a routine method for detecting methicillin-resistance in staphylococci. J Antimicrob Chemother 1996, 37:901–909.
37. Dellinger RP: Current therapy for sepsis. Infect Dis Clin North Am 1999. 13:495–509.
38. Cronin L, Cook DJ, Carlet J, et al.: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430–1439.
39. Lefering R, Neugebauer EA: Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995. 23:1294–1303.
40. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment [editorial; comment]. Crit Care Med 1997, 25:1095–1100. These authors provide a comprehensive discussion of anti-inflammatory therapies in the treatment of sepsis.
41. Murakami K, Okajima K, Uchiba M, et al.: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996, 87:642–647.